BioSpace News Archive

Phanes Therapeutics, Inc. today announced that it has entered into a research collaboration with Xyphos Biosciences, Inc. an Astellas Company.

Merck announced today that the U.S. Food and Drug Administration (FDA) has approved the addition of the intramuscular (IM) route of administration to the United States Product Insert (USPI) for Merck’s MMRV family of vaccines: M-M-R®II, VARIVAX®, and ProQuad®.

Voyager Therapeutics, Inc. today announced that Novartis AG (NYSE: NVS) has exercised its options to license novel capsids generated from Voyager’s TRACER™ capsid discovery platform for use in gene therapy programs against two undisclosed neurologic disease targets.

Axogen, Inc. today announced the appointment of Marc Began as Executive Vice President.

Tango Therapeutics, Inc. today announced that, effective March 1, 2023, the Compensation Committee of Tango Therapeutics’ Board of Directors granted non-qualified stock options to purchase an aggregate of 637,000 shares of its common stock and an aggregate of 106,250 restricted stock units (RSUs) to two new employees.

Invivyd, Inc., a clinical stage biopharmaceutical company on a mission to protect the vulnerable from serious viral infectious diseases, announces the election of VYD222 to advance into the clinic as a novel monoclonal antibody therapeutic option for COVID-19.

Ocugen, Inc. today announced the appointment of Quan A. Vu to Chief Financial Officer & Chief Business Officer.

Aclaris Therapeutics, Inc. today announced preliminary topline results from a 12-week, Phase 2a, multicenter, randomized, placebo-controlled clinical study to investigate the efficacy, safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of zunsemetinib (ATI-450), an investigational oral MK2 inhibitor, in patients with moderate to severe hidradenitis suppurativa (HS) (ATI-450-HS-201).

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system sensors for integration with automated insulin delivery (AID) systems.

Helius Medical Technologies, Inc. today announced that the Company will release its fourth quarter and full year 2022 financial results on Thursday, March 9, 2023, after the market closes.